Drug Trial Radar · NCT03195673
Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting
Last checked: Nov 20, 2026Latest source record: Dec 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 2, 2018
Primary completion
Nov 15, 2019
Study completion Dec 15, 2019
Sponsor
- Lead sponsor
- Capital Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Luhe Teaching Hospital of the Capital Medical University; Beijing Anzhen Hospital
- First posted
- Jun 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of low dosage of Terazosin in Carotid Artery Stenting
Conditions
- Carotid Artery Stenosis
Interventions
TerazosinDrug
TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
Carotid artery stentingProcedure
Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants who got New DWI Lesions (MRI)Time frame: Within 48 hours after carotid artery stenting
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China · Recruiting
The Luhe Teaching Hospital of the Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.